The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 16, 2020
Filed:
May. 31, 2018
Applicant:
Kyungpook National University Industry—academic Cooperation Foundation, Daegu, KR;
Inventors:
Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); A61K 31/7105 (2006.01); G01N 33/53 (2006.01); G01N 33/559 (2006.01); G01N 33/561 (2006.01); G01N 33/573 (2006.01); C07K 16/18 (2006.01); A01K 67/027 (2006.01); A61K 31/135 (2006.01); A61K 31/137 (2006.01); C12N 15/113 (2010.01); C12Q 1/6883 (2018.01); G01N 33/50 (2006.01); A61P 25/28 (2006.01); A61K 31/133 (2006.01); A61K 31/713 (2006.01); A61K 38/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7105 (2013.01); A01K 67/0275 (2013.01); A61K 31/133 (2013.01); A61K 31/135 (2013.01); A61K 31/137 (2013.01); A61K 31/713 (2013.01); A61K 38/005 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 25/28 (2018.01); C07K 16/18 (2013.01); C12N 15/1137 (2013.01); C12Q 1/6883 (2013.01); G01N 33/5023 (2013.01); G01N 33/53 (2013.01); G01N 33/559 (2013.01); G01N 33/561 (2013.01); G01N 33/573 (2013.01); A01K 2217/052 (2013.01); A01K 2217/075 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0312 (2013.01); A61K 48/005 (2013.01); A61K 48/0066 (2013.01); C12N 2320/30 (2013.01); C12Y 301/04012 (2013.01); G01N 33/6896 (2013.01); G01N 2333/916 (2013.01); G01N 2800/50 (2013.01); G01N 2800/52 (2013.01);
Abstract
The present invention relates to a method for treating degenerative neurological disorders in a subject in need thereof, comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising an acid sphingomyelinase (ASM) activity inhibitor or expression inhibitor as an active ingredient.